




RealRate

MEDICINAL PRODUCTS & SUBSTANCES 2022

ONCOCYTE™

Oncocyte Corp
Rank 32 of 50



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



RealRate

MEDICINAL PRODUCTS & SUBSTANCES 2022



Oncocyte Corp Rank 32 of 50

The relative strengths and weaknesses of Oncocyte Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Oncocyte Corp compared to the market average is the variable Goodwill, increasing the Economic Capital Ratio by 210% points. The greatest weakness of Oncocyte Corp is the variable Net Income, reducing the Economic Capital Ratio by 104% points.

The company's Economic Capital Ratio, given in the ranking table, is -148%, being 81% points above the market average of -229%.

Input Variable	Value in 1000 USD
Assets Hidden Reserves	0
Assets, Current	39,143
Assets, Non-Current	264
General and Administrative Expense	37,688
Goodwill	109,929
Liabilities Hidden Reserves	0
Liabilities, Current	14,120
Liabilities, Non-Current	0
Other Assets	10,227
Other Compr. Net Income	37
Other Expenses	21,359
Other Liabilities	80,226
Other Net Income	854
Property, Plant and Equipment, Net	0
Research and Development	13,631
Revenues	7,727

Output Variable	Value in 1000 USD
Liabilities	94,346
Assets	159,563
Expenses	72,678
Market Value Liabilities	94,346
Market Value Assets	159,563
Stockholders Equity	65,217
Net Income	-64,097
Comprehensive Net Income	-64,078
Economic Capital Ratio	-148%



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai